Vebeglogene autotemcel is under clinical development by Lantu Biopharma and currently in Phase II for Beta Thalassaemia.
ArMaDa clinical trial is set to assess the safety and efficacy of unilateral subretinal administration of OCU410 in subjects with GA ...
The multinational, multicenter, prospective RESTORE Study is the 5-year follow-up study of the phase 3 clinical RESCUE and ...
Only a few patients have undergone an intensive gene therapy cure for sickle cell disease since it was approved by the FDA ...
A phase 3 trial highlights betibeglogene autotemcel as a potentially curative gene therapy for severe transfusion-dependent β ...
Researchers at Children's Hospital of Philadelphia (CHOP) and the University of Pennsylvania Perelman School of Medicine ...
After raising AU$16.75 million (US$10.4 million) in a series A round, Celosia Therapeutics Pty Ltd. is heading toward the clinic with its novel gene therapy that targets TDP-43, a protein directly ...
Bryan Johnson, who’s spending hundreds of millions of dollars on treatments designed to extend his life, is many things to ...
ScreenRant on MSN3d
What Is Minicircle? Bryan Johnson's Honduras Gene Therapy Company From Netflix's Don't Die ExplainedThe Man Who Wants to Live Forever introduced many viewers to the Minicircle company, and here's what the organization ...
The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future ...
Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...
Learn about pediatric low-grade glioma symptoms, causes, diagnosis, and treatment. Understand risk factors and prevention to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback